Profile photo Helena Verkooijen

Helena Verkooijen

Full Professor

Strategic program(s):

Biography

Professor of Evaluation of Image-Guided Treatment, dedicated to improve the life of people with cancer. Committed to full integration of clinical research in routine patient care in order to facilitate undelayed evidence-based implementation of innovations in oncology. 
Medical-scientific director of the Imaging Cluster (incorporating the departments of Radiology, Radiotherapy, Nuclear Medicine and Clinical Physics) at the Antoni van Leeuwenhoek hospital. Leader (PI) of several international research consortia and academic industrial partnership, based at UMC Utrecht. Strong background in teaching and development of educational modules at graduate and postgraduate level. Large international academic experience in Europe and Asia. Experienced speaker, moderator, panel member, and member of the supervisory board of the Rotterdam Eye Hospital. 
Sharp analytic mind, strong drive and ability to turn ideas into reality. Connector. Passionate about encouraging and facilitating colleagues, team members, and (PhD) students to bring out the best in themselves and each other.

Strategic program(s):

Contact

Research groups

Evaluation of imaging and image-guided Interventions

Research aim

The pace of innovation in (AI driven) imaging/image-guided interventions in oncology is high; the window of opportunity for evaluation narrow. We aim to learn from every patient, in order to facilitate evidence-based implementation of innovation.

Go to group

Recent publications

Acute toxicity and quality of life after margin reduction using a sub-fractionation workflow for stereotactic radiotherapy of localized prostate cancer on a 1.5 Tesla MR-linac T A Lalmahomed, T Willigenburg, S M G van de Pol, E N de Groot-van Breugel, L M W Snoeren, J Hes, H H E van Melick, H M Verkooijen, J C J de Boer, J R N van der Voort van Zyp
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2025, vol. 207
Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy Britt A.M. Jansen, Claudia A. Bargon, Maria A. Bouman, Dieuwke R.Mink van der Molen, Emily L. Postma, Femke van der Leij, Erik Zonnevylle, Quinten Ruhe, Sven E. Bruekers, Wiesje Maarse, Sabine Siesling, Danny A. Young-Afat, Annemiek Doeksen, Helena M. Verkooijen,
Breast Cancer Research and Treatment, 2025, vol. 210, p.759–769
Side-effects in women treated with adjuvant endocrine therapy for breast cancer L. M. Rademaker, R. Gal, A. M. May, M. C.T. Batenburg, F. van der Leij, R. M. Bijlsma, H. M. Verkooijen, A. Doeksen, M. F. Ernst, D. J. Evers, C. C. van der Pol, E. M. Monninkhof
Breast, 2025, vol. 80
Risk Factors for the Development of Neurological Deficits in Metastatic Spinal Disease Eline H. Huele, Roxanne Gal, Wietse S.C. Eppinga, Helena M. Verkooijen, John E. O’Toole, Ilya Laufer, Daniel M. Sciubba, Cordula Netzer, Wouter Foppen, Arjun Sahgal, Michael G. Fehlings, Sheng fu L. Lo, Charles G. Fisher, Laurence D. Rhines, Jeremy J. Reynolds, Aron Lazary, Alessandro Gasbarrini, Nicolas Dea, Michael H. Weber, Jorrit Jan Verlaan
Global Spine Journal, 2025, vol. 15, p.93S-103S
Treatment time and learning curve analysis of 1.5 T MR-Linac workflows led by radiation oncologists or therapists J. M. Westerhoff, F. J. Raaijmakers, L. A. Daamen, E. N. de Groot-van Breugel, L. T.C. Meijers, J. R.N. van der Voort van Zyp, J. J.C. Verhoeff, S. Mook, H. M. Verkooijen, M. P.W. Intven
Clinical and translational radiation oncology, 2025, vol. 51
Tailored guidance to apply the Estimand framework to Trials within Cohorts (TwiCs) studies R. Gal, R. Kessels, K. Luijken, L. A. Daamen, D. R. Mink van der Molen, S. A.M. Gernaat, A. M. May, H. M. Verkooijen, P. M. van de Ven
Global Epidemiology, 2024, vol. 8

External positions

Lid raad van toezicht - Toezicht - BCN / Alexander Monro Ziekenhuis

Lid raad van toezicht - Toezicht - Oogziekenhuis Rotterdam

Lid Commissie Exploratie - Beoordeling wetenschappelijke aanvragen - KWF Kankerbestrijding

bestuurslid - geen - JM Fentener van Vlissingen Fonds

Spreker - ja - Elekta

Lid Wetenschappelijke Adviesraad Landelijk ReferentieCentrum Bevolkingsonderzoek - inhoudelijk - LRCB